Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC) (TLH-202)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2013 by Tiltan Pharma Ltd..
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Tiltan Pharma Ltd.
ClinicalTrials.gov Identifier:
NCT00684970
First received: May 22, 2008
Last updated: December 4, 2013
Last verified: December 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)